However, the T-cell is only fully activated for cancer cell killing after it receives a second "costimulatory" signal, most powerfully via the CD28 costimulatory receptor. Regeneron's CD3 and CD28 ...

17 presentations to highlight Regeneron's investigational pipeline including checkpoint inhibitors, CD3 bispecifics and CD28 costimulatory bispecifics ...

BofA reinstated coverage of Regeneron (REGN) with an Underperform rating and $565 price target The firm calls Regeneron a “high-quality company,” with “lots to like generally,” but thinks ...

Regeneron Pharmaceuticals, a leading biotechnology company announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.